Sevoflurane |
| Catalog No.: GC19481 |
A halogenated ether with anesthetic properties
Sample solution is provided at 25 µL, 10mM.
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
;)
Quality Control & SDS
- View current batch:
-
Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Sevoflurane is a halogenated ether with anesthetic properties.1 It enhances the activity of GABAA and glycine receptors and inhibits the activity of nicotinic acetylcholine receptors (nAChRs) and glutamate receptors. Sevoflurane enhances the responses of α2β1 subunit-containing GABAA and α1 subunit-containing glycine receptors at submaximal agonist concentrations in HEK293 cells (EC50s = 0.45 and 0.36 mM, respectively).2 Sevoflurane (360 µM) also increases the amplitude of GABAA receptor responses to GABA stimulation for receptors with an α1β2γ2 subunit composition.3 It inhibits binding of the high affinity nicotinic agonist epibatidine to nAChRs in mouse brain membranes (IC50 = 0.77 mM).4 Formulations containing sevoflurane have been used in the induction and maintenance of general anesthesia.
Reference:
[1]. Campagna, J.A., Miller, K.W., Phil, D., et al. Mechanisms of actions of inhaled anesthetics N. Engl. J. Med. 348(21), 2110-2124 (2003).
[2]. Krasowski, M.D., and Harrison, N.L. The actions of ether, alcohol and alkane general anaesthetics on GABAA and glycine receptors and the effects of TM2 and TM3 mutations Br. J. Pharmacol. 129(4), 731-743 (2000).
[3]. Nishikawa, K., and Harrison, N.L. The actions of sevoflurane and desflurane on the gamma-aminobutyric acid receptor type A: Effects of TM2 mutations in the alpha and beta subunits Anesthesiology 99(3), 678-684 (2003).
[4]. Rada, E.M., Tharakan, E.C., and Flood, P. Volatile anesthetics reduce agonist affinity at nicotinic acetylcholine receptors in the brain Anesth. Analg. 96(1), 108-111 (2003).
| Cas No. | 28523-86-6 | SDF | |
| Chemical Name | 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)-propane | ||
| Canonical SMILES | FCOC(C(F)(F)F)C(F)(F)F | ||
| Formula | C4H3F7O | M.Wt | 200.1 |
| Solubility | DMF: miscible,DMSO: miscible,Ethanol: miscible,PBS (pH 7.2): miscible | Storage | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5 (Based on Reviews and 14 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *